SU-GG-T-135: Comparison of Treatment Planning Systems in Elekta Volumetric Modulated Arc Therapy (Elekta VMAT) - Prostate Cancer Study

2010 ◽  
Vol 37 (6Part17) ◽  
pp. 3215-3215
Author(s):  
A Haga ◽  
S Kida ◽  
Y Okano ◽  
S Itoh ◽  
T Matsuura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Planning ◽  
Volumetric Modulated Arc Therapy ◽  
Planning Systems ◽  
Cancer Study ◽  
Treatment Planning Systems ◽  
Arc Therapy ◽  
Prostate Cancer Study

scholarly journals Comparison between two treatment planning systems for volumetric modulated arc therapy optimization for prostate cancer

2014 ◽  
Vol 30 (1) ◽  
pp. 2-9 ◽  
Author(s):  
Caroline Lafond ◽  
Frédéric Gassa ◽  
Christophe Odin ◽  
Gaël Dréan ◽  
Justine Even ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Planning ◽  
Volumetric Modulated Arc Therapy ◽  
Planning Systems ◽  
Treatment Planning Systems ◽  
Arc Therapy

scholarly journals Delivery Parameter Variations and Early Clinical Outcomes of Volumetric Modulated Arc Therapy for 31 Prostate Cancer Patients: An Intercomparison of Three Treatment Planning Systems

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Shinichi Tsutsumi ◽  
Masako N. Hosono ◽  
Daisaku Tatsumi ◽  
Yoshitaka Miki ◽  
Yutaka Masuoka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Volumetric Modulated Arc Therapy ◽  
Planning Systems ◽  
Treatment Planning Systems ◽  
Dose Volume ◽  
Parameter Variations ◽  
Arc Therapy ◽  
The Mean ◽  
Mean Dose Rate ◽  
Early Clinical Outcomes

We created volumetric modulated arc therapy (VMAT) plans for 31 prostate cancer patients using one of three treatment planning systems (TPSs)—ERGO++, Monaco, or Pinnacle—and then treated those patients. A dose of 74 Gy was prescribed to the planning target volume (PTV). The rectum, bladder, and femur were chosen as organs at risk (OARs) with specified dose-volume constraints. Dose volume histograms (DVHs), the mean dose rate, the beam-on time, and early treatment outcomes were evaluated and compared. The DVHs calculated for the three TPSs were comparable. The mean dose rates and beam-on times for Ergo++, Monaco, and SmartArc were, respectively, 174.3 ± 17.7, 149.7 ± 8.4, and 185.8 ± 15.6 MU/min and 132.7 ± 8.4, 217.6 ± 13.1, and 127.5 ± 27.1 sec. During a follow-up period of 486.2 ± 289.9 days, local recurrence was not observed, but distant metastasis was observed in a single patient. Adverse events of grade 3 to grade 4 were not observed. The mean dose rate for Monaco was significantly lower than that for ERGO++ and SmartArc (P<0.0001), and the beam-on time for Monaco was significantly longer than that for ERGO++ and SmartArc (P<0.0001). Each TPS was successfully used for prostate VMAT planning without significant differences in early clinical outcomes despite significant TPS-specific delivery parameter variations.

scholarly journals Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0257216
Author(s):  
Jongmoo Park ◽  
Jaehyeon Park ◽  
Sean Oh ◽  
Ji Woon Yea ◽  
Jeong Eun Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Planning ◽  
Volumetric Modulated Arc Therapy ◽  
Planning System ◽  
Treatment Planning System ◽  
Target Coverage ◽  
Arc Therapy ◽  
Femoral Heads ◽  
Treatment Volume ◽  
Dose Constraints

We aimed to compare the volumetric-modulated arc therapy (VMAT) plans with or without multi-criteria optimization (MCO) on commercial treatment-planning systems (Eclipse, Varian Medical System, Palo Alto, CA, USA) for patients with prostate cancer. We selected 25 plans of patients with prostate cancer who were previously treated on the basis of a VMAT plan. All plans were imported into the Eclipse Treatment Planning System version 15.6, and re-calculation and re-optimization were performed. The MCO plan was then generated. The dosimetric quality of the plans was evaluated using dosimetric parameters and dose indices that account for target coverage and sparing of the organs at risk (OARs). We defined the rectum, bladder, and bilateral femoral heads. The VMAT-MCO plan offers an improvement of gross treatment volume coverage with increased minimal dose and reduced maximal dose. In the planning treatment volume, the Dmean and better gradient, homogeneity, and conformity indexes improved despite the increasing hot and cold spots. When implemented through the MCO plan, a steeper fall off the adjacent OARs in the overlap area was achieved to obtain lower dose parameters. MCO generated better sparing of the rectum and bladder through a tradeoff of the increasing dose to the bilateral femoral heads within the tolerable dose constraints. Compared with re-optimization and re-calculation, respectively, significant dose reductions were observed in the bladder (241 cGy and 254 cGy; p<0.001) and rectum (474 cGy and 604 cGy, p<0.001) with the MCO. Planning evaluation and dosimetric measurements showed that the VMAT-MCO plan using visualized navigation can provide sparing of OAR doses without compromising the target coverage in the same OAR dose constraints.

Sign in / Sign up

Export Citation Format

Share Document